Nichi-Iko Of Japan To Buy Major Stake In Aprogen Of S. Korea
This article was originally published in PharmAsia News
Executive Summary
Japan's Nichi-Iko Pharmaceutical is buying a third of South Korea's Aprogen to gain the start-up's bioengineered drugs to sell in the Japanese market